Fibrocell Science (FCSC) vs. Its Rivals Head-To-Head Survey
Fibrocell Science (NASDAQ: FCSC) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Fibrocell Science to similar companies based on the strength of its earnings, dividends, risk, valuation, analyst recommendations, profitability and institutional ownership.
Earnings & Valuation
This table compares Fibrocell Science and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Fibrocell Science||$252,000.00||-$18.04 million||-1.56|
|Fibrocell Science Competitors||$207.80 million||-$2.19 million||-0.33|
Fibrocell Science’s rivals have higher revenue and earnings than Fibrocell Science. Fibrocell Science is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Fibrocell Science has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Fibrocell Science’s rivals have a beta of 1.67, suggesting that their average stock price is 67% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Fibrocell Science and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Fibrocell Science Competitors||790||2961||6462||145||2.58|
Fibrocell Science currently has a consensus price target of $5.53, suggesting a potential upside of 80.83%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 5.17%. Given Fibrocell Science’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Fibrocell Science is more favorable than its rivals.
Insider and Institutional Ownership
54.7% of Fibrocell Science shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 2.1% of Fibrocell Science shares are owned by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Fibrocell Science and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Fibrocell Science Competitors||-11,914.72%||-416.04%||-47.51%|
Fibrocell Science Company Profile
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.